Skip to main navigation Skip to search Skip to main content

Durvalumab (MEDI4736; anti-PD-L1 inhibitor): To shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy

  • Seoul National University

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)S454-S457
JournalTranslational Cancer Research
Volume5
DOIs
StatePublished - 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this